|
Convatec Group PLC said it will set out the ‘next chapter’ of its growth plan at its capital markets day on Thursday. The London-based medical products and technologies provider said the new ’Accelerate’ plan will help it to achieve its recently upgraded medium-term guidance of between 6% and 8% annual organic revenue growth. The firm said the new strategy is ‘underpinned by the strongest pipeline of innovation in Convatec’s history and will see accelerating sustainable and profitable growth’. ‘Accelerate represents an evolution of the company’s previous FISBE strategy, which transformed Convatec into a chronic care leader in each of its care categories,’ Convatec said. ‘Under FISBE, Convatec pivoted to sustainable and profitable growth, consistently delivering against strategic targets with five years of broad-based, resilient revenue growth. Convatec now has differentiated products winning share and significant growth opportunities across categories, products and geographies.’ Under the new plan, Convatec said it will target ‘customer-focused growth’ as well as ‘technology and innovation’. As well as the organic growth target, Convatec’s medium-term goals also include an adjusted operating margin between 24% and 26%, with annual double-digit adjusted earnings per share growth. In 2025, organic revenue climbed 6.4%, or 4.8% including InnovaMatrix. The adjusted operating margin was 22.3%. Adjusted diluted EPS rose 16%. ‘Chronic care markets are underpinned by long-term structural growth trends including ageing populations and the rising prevalence of chronic conditions,’ said Chief Executive Officer Jonny Mason. ‘This creates opportunities to serve more people living with chronic conditions. Our innovation pipeline of new products is stronger than ever and represents our commitment to deliver meaningful advances in patient care.’ Shares in Convatec were down 0.1% at 224.60 pence on Thursday morning in London. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
